Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shenzhen Haibin Pharmaceutical is a prominent Chinese pharmaceutical company specializing in the research, development, and large-scale manufacturing of antibiotic medications. As a core subsidiary of Joincare Pharmaceutical Group, the company has established itself as a leading global supplier of carbapenem antibiotics, including Meropenem and Imipenem. Its facilities are designed to meet international standards, holding certifications such as EU-GMP and US FDA approvals for various products. The company's portfolio extends beyond anti-infectives to include treatments for respiratory and cardiovascular diseases. Shenzhen Haibin operates integrated production lines that cover both Active Pharmaceutical Ingredients (APIs) and finished dosage forms, serving both domestic and international markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shenzhen Haibin.